PT Kalbe Farma Tbk (PTKFY) Stock Price & Analysis
PT Kalbe Farma Tbk (PTKFY) — price $8.20 (+5.13%), as of the Oct 5, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
PT Kalbe Farma Tbk · PTKFY
PT Kalbe Farma Tbk. is a leading Indonesian pharmaceutical company specializing in a diverse range of healthcare products, including prescription medications, over-the-counter drugs, and nutritional products.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.20 | |
| Change on the day | +5.13% | |
| 52-week range | $7.63 – $16.36 | |
| Price / earnings (trailing) | 9.17 | |
| Shares traded on the day | 400 |
Price & events
Other perspectives
Council score for PT Kalbe Farma Tbk (PTKFY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the PTKFY film — every key number, told as a short cinematic story
~2 min · open the film
What is PT Kalbe Farma Tbk (PTKFY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. PT Kalbe Farma Tbk (PTKFY) is the company analyzed here. It employs 12,835 people and is led by Bernadette Ruth Irawati Setiady. In Q2 FY2026 it reported revenue of $547M and net income of $50M.
What do the latest results show for PT Kalbe Farma Tbk (PTKFY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $547M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $547M | $50M | $0.22 (diluted) |
| Q1 FY2026 | $548M | $58M | $0.26 (diluted) |
| Q4 FY2025 | $521M | $58M | $0.25 (diluted) |
| Q3 FY2025 | $500M | $37M | $0.17 (diluted) |
What are the financial strengths and risks for PT Kalbe Farma Tbk (PTKFY)?
Short answer
The distress and quality screens read Altman Z 3.24 · Piotroski F 6. Trailing ratios: ROE 15.6% · ROA 11.3% · current ratio 3.56 · earnings yield 10.4% · free-cash-flow yield 7.1%.
Investor Questions: PTKFY Stock
These answers are editorial: 1 of these 8 answers is drawn from the PTKFY research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PTKFY a good stock to buy?
Stock Expert AI does not rate PTKFY buy, sell or hold. PT Kalbe Farma Tbk has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PTKFY stock price today?
The last price recorded on this page for PT Kalbe Farma Tbk (PTKFY) is $8.20, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for PTKFY?
Main risks for PT Kalbe Farma Tbk. include currency fluctuations that may affect the valuation of its ADR, regulatory changes that could impact product approvals, and economic downturns that might reduce consumer spending on healthcare products.
What are the key factors to evaluate for PTKFY?
Evaluate PTKFY on fundamentals, analyst consensus, and risk factors. P/E: 9.17x. Kalbe Farma's potential to innovate in this space could provide new revenue opportunities and enhance patient engagement. Not financial advice.
How frequently does PTKFY data refresh on this page?
PTKFY's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PTKFY's recent stock price performance?
PT Kalbe Farma Tbk (PTKFY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in Indonesia's pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PTKFY overvalued or undervalued right now?
PT Kalbe Farma Tbk (PTKFY) trades at 9.17x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PTKFY before investing?
Before investing in PT Kalbe Farma Tbk (PTKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $8.20 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T22:54:23.960Z. | |
px.change | Change on the day | +5.13% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | +$0.40 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 9.17 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 400 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $547M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $50M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $7.63 – $16.36 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.employees | Employees | 12,835 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.ceo | Chief executive | Bernadette Ruth Irawati Setiady | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 3.24 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 15.6% · ROA 11.3% · current ratio 3.56 · earnings yield 10.4% · free-cash-flow yield 7.1% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.